抗乙型肝炎病毒药物与治疗的研究进展  

Research Advance in Anti-HBV Drugs and Treatments

作　　者：普小菲[1] 彭芳[1] 

机构地区：[1]大理学院药学与化学学院,云南大理671000

出　　处：《医学综述》2012年第6期914-916,共3页Medical Recapitulate

摘　　要：由乙型肝炎病毒引起的乙型肝炎是一种发病率高、病死率高的传染病,现已成为全球性重大的公众健康问题。目前临床上应用和正在临床研究中的抗乙型肝炎病毒药物分为免疫调节剂、核苷类和非核苷类药物,但免疫调节剂的不良反应和核苷类药物耐药性病毒株的出现使得新颖抗乙型肝炎病毒药物的研究成为热点。现对近年来抗乙型肝炎病毒药物与治疗的研究进展予以阐述,并预测其发展趋势,以推动新型高效药物的研发。Chronic hepatitis B caused by the hepatitis B virus is a communicable disease with high morbidity and high mortality,which has become an important problem of public health.Current anti-HBV drugs in clinical research and application include immunomodulators,nucleoside and non-nucleoside drugs.However,the use of immunomodulator has many side effects while that of nucleoside drugs can lead to the emergence of resistant viruses.Hence,treatment of chronic hepatitis B needs new anti-HBV drugs.Here is to introduce the research advance in drugs and treatments of anti-HBV and forecasts the tendency to promote the researching and developing of new efficient drugs.

关 键 词：抗乙型肝炎病毒 药物 治疗 

分 类 号：R978.7[医药卫生—药品]